Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012

An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 6 and 11, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012, the adenovirus infects and expresses the HPV-6/11 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against cells infected with HPV-6/11, thereby inducing tumor cell lysis. HPV6/11 play a key role in the development of recurrent respiratory papillomatosis (RRP).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:therapeutic cancer vaccine PRGN-2012
Code name:PRGN 2012
PRGN-2012
PRGN2012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search